Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mesothelin-targeted CAR-NK cell injection
- Development stage
- Unknown
- Lead developer
- Guojian Chengnuo Biotechnology
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intraperitoneal
01
Overview
Mesothelin-targeted CAR-NK cell injection (CN-NK01) is an investigational allogeneic chimeric antigen receptor (CAR) natural killer (NK) cell therapy developed by National Health Chengno Biotechnology (Beijing) Co., Ltd. The therapy consists of NK cells engineered to express a CAR that specifically targets mesothelin (MSLN), a cell-surface glycoprotein that is highly expressed in various solid tumors, including epithelial ovarian cancer, but has limited expression in normal tissues. By utilizing NK cells, this approach aims to provide a potent anti-tumor response with a lower risk of graft-versus-host disease (GvHD) and cytokine release syndrome (CRS) compared to traditional CAR-T cell therapies. In clinical development, the injection is administered intraperitoneally to treat patients with mesothelin-positive, platinum-resistant advanced epithelial ovarian cancer, focusing on safety, tolerability, and preliminary anti-tumor efficacy.
- Other names
- MSLN-CAR-NKmesothelin-targeted CAR-NK cell injectionmesothelin-targeted chimeric antigen receptor natural killer cell injection
02
Targets
Mesothelin
Beyond the preview
Go deeper on mesothelin-targeted CAR-NK cell injection.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mesothelin-targeted CAR-NK cell injection.